Day: August 10, 2022

– Successfully Completed the Tender Offer for Aspire Global on June 16, 2022 – – Second Quarter Revenues and Share of NPI Revenues Interest totaled $31.3 million, up 46.4% year-over-year – – Updates Full Year 2022 Revenue and Share of NPI Revenues Guidance to $194 million to $208 million reflecting completion of Aspire Global Tender – LUXEMBOURG, Aug. 10, 2022 (GLOBE NEWSWIRE) — NeoGames S.A. (Nasdaq: NGMS) (“NeoGames” or the “Company”), a technology-driven provider of end-to-end iLottery and iGaming solutions, announced today financial results for the second quarter ended June 30, 2022. Moti Malul, Chief Executive Officer of NeoGames, said: “During the quarter, we were excited to complete our tender offer for the shares of Aspire Global plc (“Aspire Global”), a truly transformative transaction that positions us as...

WOBURN, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today provided a business update and reported financial results for the quarter ended June 30, 2022.    “This has been a historic year for Comera, as we have transitioned into a public company, completed a significant collaboration with Intas, and made important progress in strengthening our team and capabilities. These advancements have us well positioned to execute on our long-term strategy to leverage our SQore™ platform,” said Jeff Hackman, President, Chief Executive Officer and Chairman of Comera. “Transforming the delivery of biologics from intravenous (IV) to subcutaneous (SQ) forms has...

HAMILTON, BERMUDA, August 10, 2022 – DHT Holdings, Inc. (NYSE:DHT) (“DHT” or the “Company”) today announced its results for the quarter ended June 30, 2022. The full report is available here and in the below attachment. About DHT Holdings, Inc. DHT is an independent crude oil tanker company. Our fleet trades internationally and consists of crude oil tankers in the VLCC segment. We operate through our integrated management companies in Monaco, Norway and Singapore. You may recognize us by our renowned business approach as an experienced organization with focus on first rate operations and customer service; our quality ships; our prudent capital structure that promotes staying power through the business cycles; our combination of market exposure and fixed income contracts for our fleet; our counter cyclical philosophy with respect to investments,...

Matterport Q2 2022 Infographic Matterport Q2 2022 InfographicSubscription revenue rose 20% year-over-year, above Company guidance Services revenue increased 74% year-over-year Q2 GAAP loss per share of $0.23 Non-GAAP loss per share of $0.12, better than Company guidance Matterport increases full year revenue guidance range to $132 to $138 million, narrows full year guidance range for non-GAAP loss per share to $0.46 to $0.50 Balance sheet remains strong with $562 million cash and investments and no debtSUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Matterport, Inc. (Nasdaq: MTTR) (“Matterport” or the “Company”), the leading spatial data company driving the digital transformation of the built world, today announced financial results for the quarter ended June 30, 2022. “We delivered another strong quarter, increasing...

Recently announced intent to rename and rebrand to Lifecore Biomedical, along with leadership and Board changes Lifecore segment revenues increased 6.9% to $27.6 million in fiscal fourth quarter, and increased 11.5% to $109.3 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment EBITDA increased 14.5% to $8.8 million in fiscal fourth quarter, and increased 16.4% to $28.5 million for the full fiscal year 2022, as compared to the respective prior year periods Lifecore segment adjusted EBITDA increased 15.9% to $8.9 million in fiscal fourth quarter, and increased 17.9% to $28.9 million for the full fiscal year 2022, as compared to the respective prior year periods Introduces fiscal 2023 full year guidance for Lifecore SANTA MARIA, Calif. and MINNEAPOLIS, Minn., Aug. 10, 2022 (GLOBE NEWSWIRE)...

Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities Cancer Detection revenue grew 10.4% compared to the second quarter of 2021 Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H., Aug. 10, 2022 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three and six months ended June 30, 2022. Recent Highlights:Increased demand for subscription and SaaS-based models is accelerating customer acquisition and establishing predictable, long-term revenue streams. Compelling new research published in Science Translational Medicine finds ProFound AI Risk is up to 2.4 times more accurate...

NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. (“Getty Images”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the second quarter ended June 30, 2022. “We are pleased to report strong second quarter results as we enter the public markets following the successful completion of our business combination last month with CC Neuberger,” said Craig Peters, Chief Executive Officer of Getty Images. “For more than 27 years Getty Images has been a leading visual content creator and marketplace and we are excited to continue to execute our growth strategy through this next chapter, supported by our strong balance sheet and continued profitability.” Second Quarter 2022 Financial Summary:Revenue of $233.3 million, grew 4.1% year over year. On a currency...

GUILFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world’s first FDA-cleared portable MRI system™, today reported financial results for the quarter ended June 30, 2022. Management will host a corresponding conference call today at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. “We continue to build awareness of Swoop’s immense value proposition, deepen our customer relationships, and drive adoption in new hospitals,” said Scott Huennekens, Interim President and CEO of Hyperfine. “We placed 9 commercial systems in the second quarter, including through our recent expansion to Australia and New Zealand – a new geography for Hyperfine – and we continue to build our pipeline for the second half of the year and beyond.” Second Quarter 2022 Financial ResultsRevenues for...

Third party net sales of $233.4 million Net loss of ($8.7) million; net loss margin of (3.7%); adjusted net income[1] of $17.6 million Diluted EPS of ($0.33); adjusted diluted EPS[1] of $0.67 Adjusted EBITDA[1] of $31.3 million; adjusted EBITDA margin[1] of 13.4% Cash and cash equivalents of $130.1 million at June 30, 2022, up from $104.3 million at March 31, 2022WESTMINSTER, Colo., Aug. 10, 2022 (GLOBE NEWSWIRE) — ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the quarter ended June 30, 2022. Management will host a corresponding conference call today, August 10, 2022, at 4:30 p.m. Eastern Time. “We continue to make progress towards our most vital commercial initiatives in both our dental and spine segments. Within dental, we recently launched...

Second quarter revenue grew 32% compared to prior year FREMONT, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsTotal revenue was $40.2 million for the second quarter, representing a 32% increase over the corresponding quarter of 2021 Expanded the installed base to 1,356 instruments, with 130 instrument placements during the second quarter Received CE marking for a series of single-color cFluor® reagents and a 6-color TBNK kit, as Cytek moves to make total cell analysis solutions available for clinical applications in the European market“I am encouraged by our progress in the second quarter, capping off a strong first half of 2022,” said Dr. Wenbin Jiang, CEO of Cytek...